Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2014 May 6;201:185–190. doi: 10.1016/j.snb.2014.04.011

Virus purification and enrichment by hydroxyapatite chromatography on a chip

Miyako Niimi a, Taisuke Masuda b,⁎, Kunihiro Kaihatsu c, Nobuo Kato c, Shota Nakamura d, Takaaki Nakaya e, Fumihito Arai b
PMCID: PMC7111472  PMID: 32288247

Highlights

  • •

    We develop a microfluidic chip to purify and enrich virus by hydroxyapatite chromatography.

  • •

    We examine purification and enrichment of the virus.

  • •

    The viruses were isolated from the mixture of virus and protein.

  • •

    The virus concentration was increased by hydroxyapatite chromatography.

Keywords: Microfluidic chip, Virus purification, Virus enrichment, Hydroxyapatite chromatography, Infectious disease

Abstract

The spread of infectious diseases has become a global health concern. In order to diagnose infectious diseases quickly and accurately, next-generation DNA sequencing techniques for genetic analysis of infectious viruses have been developed rapidly. However, it takes a very long time to pretreat clinical samples for genetic analysis using next-generation sequencers. We have therefore developed a microfluidic chromatography chip that can purify and enrich viruses in a sample using hydroxyapatite particles packed in a micro-column. We demonstrated the purification of virus from a mixture of virus and FBS protein, and enrichment of the virus using this novel microfluidic chip.

1. Introduction

The spread of infectious diseases has become a global health concern. In 2002, an outbreak of atypical pneumonia, referred to as severe acute respiratory syndrome (SARS) and first identified in Guangdong Province, China, occurred and spread to several countries [1], [2]. In total, 8273 cases and 775 deaths attributed to SARS were reported in multiple countries according to the World Health Organization (WHO). In April 2009, the outbreak of a novel influenza A H1N1 virus in Mexico spread globally and developed into the first human influenza pandemic in 40 years [3], [4]. To diagnose infectious diseases quickly and accurately, DNA sequencers for genetic analysis of infectious viruses have been developed rapidly. Newly developed “next-generation” sequencing technologies for massively parallel DNA sequencing are in fairly widespread use at present [5], [6]. However, in order to diagnose infectious diseases using DNA sequences, the virus in the clinical sample must be purified and enriched in concentration before DNA sequencing [7]. These pretreatment processes are labor-intensive, cumbersome and time consuming. There is therefore need to speed up the pretreatment of clinical samples before DNA sequencing to complement the throughput of DNA sequencers. We here describe a novel microfluidic chip for purifying and enriching viruses. The microfluidic chip has many advantages; it requires only a small work place, a small sample volume, an enclosed region, and is comparatively low cost.

Tiselius et al. [8] first described protein purification by hydroxyapatite liquid chromatography in 1956. Since then, hydroxyapatite chromatography has been used extensively for the purification and fractionation of various biochemical substances such as protein [9], [10], [11], bacteriophages [12], and viruses [13], [14]. Hydroxyapatite (Ca10(PO4)(OH)2) is a very complex crystalline compound to which a variety of substances adsorb. It has been used extensively as a matrix for the purification and fractionation of an array of biochemical substances, including enzymes, nucleic acids, hormones, and viruses [15]. Many researchers have reported that the interaction between hydroxyapatite and an electrically charged adsorbate is due to ion exchange or static attraction [16], [17].

We here describe a microfluidic chip developed for hydroxyapatite chromatography. Hydroxyapatite particles were packed in a micro-column and on-chip chromatography has been conducted to purify and enrich Newcastle disease virus.

2. Materials and methods

2.1. Design of and theory behind the microfluidic chip

Fig. 1(a) shows the concept of the microfluidic chip for virus purification and enrichment by on-chip hydroxyapatite chromatography. Fig. 1(b) shows the microfluidic chip fabricated using photolithography. The hydroxyapatite used was Ceramic Hydroxyapatite Type II Support (CHT; BIO-RAD, Hercules, CA, USA), with a particle diameter of 40 μm. The microfluidic chip has a column for hydroxyapatite chromatography and a pair of switching valves. Upstream and downstream of the column, 50-μm-diameter cylindrical micropillars placed at 20-μm intervals hold the hydroxyapatite particles in the column, as shown in Fig. 1(b). Hydroxyapatite particles are introduced into the column through inlet 1. The sample and the elution buffers are introduced into the column through inlet 2.

Fig. 1.

Fig. 1

Open in a new tab

(a) Concept of the microfluidic chip for purification and enrichment of virus using hydroxyapatite chromatography. The microfluidic chip has a column for hydroxyapatite chromatography and a pair of switching valves. Hydroxyapatite particles are introduced into the column through inlet 1. The sample is introduced into the column through inlet 2 and both viruses and impurities in the sample are adsorbed onto the surface of hydroxyapatite particles. Then, an elution buffer is introduced into the column to elute the impurities such as proteins. Then, another elution buffer is introduced into the column to elute the viruses.

(b) The fabricated microfluidic chip. Upstream and downstream of the column, 50-μm-diameter cylindrical micropillars placed at 20-μm intervals hold the hydroxyapatite particles in the column. The diameter of the hydroxyapatite particles is 40 μm.

2.2. Fabrication of the microfluidic chip

The microfluidic chip consists of a polydimethylsiloxane (PDMS) microchannel and a PDMS substrate. Fig. 2 shows the processes used to fabricate a PDMS (Silpot 184, Toray-Dow Corning Co., Tokyo, Japan) microchannel and bond it to a PDMS substrate. A PDMS microchannel was produced by replica molding using a master mold fabricated by photolithography [18]. A negative-type photoresist (SU-8 3050, Kayaku MicroChem Co. Ltd., Tokyo, Japan) was spin-coated on a silicon substrate. Spin-coating condition was 1000 rpm for 30 s. After prebaking at 95 °C for 3 h, ultraviolet light was irradiated through a photomask to produce a microchannel pattern using a mask aligner (MJB-3, Suss Microtec, Garching, Germany). After post-exposure baking at 65 °C for 30 s and at 95 °C for 60 s, the substrate was then developed in PM thinner for 8 min and rinsed in ethanol. The channel was 100 μm high. Unpolymerized PDMS (resin:catalyst = 10:1) was poured into the mold and cured in an oven at 90 °C for 20 min. The replica was then peeled from the master and the PDMS microchannel was ultrasonically rinsed in ethanol. The PDMS microchannel with outlet, inlet, drain and sample recovery chamber holes and the PDMS substrate were then treated with oxygen plasma (CUTE-MP, UVOTECH Systems, Concord, CA, USA) to increase its adhesion to the PDMS substrate. After assembling the PDMS microchannel and the PDMS substrate, it was heated in oven at 145 °C for 20 min. Then silicone microtubes with an inside diameter of 1 mm and an outside diameter of 2 mm were assembled into the holes in the PDMS layer to connect the microchannel.

Fig. 2.

Fig. 2

Open in a new tab

Fabrication process of the proposed microfluidic chip. The chip consists of a PDMS microchannel and a PDMS substrate. The PDMS microchannel was produced by replica molding using a master mold fabricated by photolithography.

2.3. Switching valve

Impurities in the sample are guided towards the drain port, while the purified viruses are guided towards the sample recovery chamber by a pair of switching valves. Fig. 3 shows the fabrication process for a pair of switching valves. Two 8-mm-diameter holes were punched in the microfluidic chip using a biopsy punch. The PDMS disks in the biopsy punch were reinserted into the holes in the microfluidic chip to act as a pair of switching valves. The valves are opened or closed by rotation of the PDMS disks. This switching valve has the important advantage of being very easy to fabricate. To decrease the risk of leakage from the side of the valve, parylene thin film about 800 nm thick was coated on the side surface of each switching valve by using a dix coating apparatus (DACS-LAB, KISCO, Osaka, Japan). Pressure tests of the valves uncoated and coated with parylene were conducted to demonstrate the utility of the parylene thin film by using a pressure sensor (Pressure Transducers with Amp, Copal Electronics, Tokyo, Japan).

Fig. 3.

Fig. 3

Open in a new tab

Fabrication process of a pair of switching valves. Two 8-mm-diameter holes were punched in the microfluidic chip using a biopsy punch. The PDMS disks in the biopsy punch were reinserted in the holes in the microfluidic chip to provide a pair of switching valves. The valves are opened or closed by rotation of the PDMS disks. This switching valve has the important advantage of being very easy to fabricate.

Fig. 4 shows the fabricated switching valve and illustrates that the microchannel can be switched by rotation of the valves. First, the right valve is closed and the left one is opened, allowing blue buffer to flow toward the left channel. Next, the left valve is closed and the right one is opened, allowing red buffer to flow toward the right channel. The switching valve can be easily rotated by hand. Movie S1, ESI visualizes how to rotate the switching valves.

Fig. 4.

Fig. 4

Open in a new tab

Fabricated switching valve. The proposed valves enable the microchannels to be switched by rotation of the valves. The switching valve can be easily rotated by hand.

A pressure test showed that the leak pressure of the valves, uncoated or coated with parylene, were 28.6 kPa and 52.6 kPa, respectively, indicating that coating the side of the valve with parylene thin film decreases the risk of leakage.

2.4. Virus purification

A Newcastle disease virus (NDV) [19], [20] suspension was used to demonstrate the purification and enrichment of viruses. To purify the virus, the right valve was closed and the left valve was opened, and 100 μL of a 2.5 × 105  pfu/mL NDV suspension which included FBS proteins was introduced into the column through inlet 2. Next, 100 μL of a 500 mM KCl solution was introduced into the column through inlet 2 to elute the FBS proteins. Finally, the left valve was closed and the right valve was opened, and 100 μL of a 1 M phosphate buffer was introduced into the column through inlet 2 to elute the viruses. The phosphate buffer was collected at the sample recovery chamber to detect the viruses by hemagglutination reaction [21]. PBS was used as a control for a negative result, and a pure NDV suspension was used as a control for a positive result. For the hemagglutination reaction, blood for the hemagglutination reaction was collected from laboratory volunteers, after obtaining informed consent according to the protocol approved by the Research Ethics Committee of Nagoya University. First, blood was pipetted into a 1.5-mL Eppendorf tube and washed with PBS three times. After the final wash the supernatant was aspirated and enough PBS was added to make a working solution of 2% RBCs in PBS. Next, 50 μL of the working solution was added to each well of a round-bottomed 96-well dish, then 50 μL of the sample was added to each well and mixed with the working solution. The mixture was left at room temperature for 30 min. As shown in Fig. 5(a), the negative result appears as a red dot in the center of the round-bottomed plate because the red blood cells settle out, and as shown in Fig. 5(b), the positive result forms a uniform reddish color across the well because each agglutinating molecule on the virus coat binds to multiple red blood cells to form a bridged structure.

Fig. 5.

Fig. 5

Open in a new tab

Negative control (a) and positive control (b) for the hemagglutination reaction. The negative result appears as a red dot in the center of the round-bottomed plate because the red blood cells settle out. The positive result forms a uniform reddish color across the well because each agglutinating molecule on the virus coat binds to multiple red blood cells to form a bridged structure.

2.5. Virus enrichment

To demonstrate enrichment of the virus, 1 mL of a 1.0 × 103  pfu/mL NDV suspension was introduced into the column through inlet 2. Five microfluidic chips with different shapes of microcolumn were prepared, as shown in Fig. 6 . The width and the length of the microcolumns were (A) 2 mm and 10 mm, (B) 1 mm and 10 mm, (C) 1 mm and 20 mm, (D) 1 mm and 40 mm, and (E) 0.5 mm and 40 mm. 1 M phosphate buffer (100 μL) was introduced into the column through inlet 2 to elute the viruses. The phosphate buffer was collected at the sample recovery chamber and viral RNA was extracted using High pure viral RNA kit (Roche, Basel, Switzerland). RT-PCR was carried out to estimate the enrichment efficiency. All qRT-PCR processes were conducted using Kapa SYBR® FAST One-Step qRT-PCR Kit (Kapa Biosystems, Boston, MA, USA) as described by the manufacturer. The genome of pNDV/B1 [22] was used for the quantitative evaluation of the virus nucleic acids. The primer sets used for pNDV/B1 were 5′-AGTGATGTGCTCGGGCCTTC-3′ and 5′-AGTGATGTGCTCGGGCCTTC-3′. The NDV-specific primer and protocol used were as described elsewhere [22]. The thermal cycling protocol for real-time RT-PCR was as follows: a cDNA synthesis step at 42 °C for 5 min, an inactivation RT step at 95 °C for 2 min, 45 cycles of denaturation at 95 °C for 3 s, annealing and extension at 60 °C for 20 s. Real-time RT-PCR was conducted using an Eco™ Real-Time PCR System (illumina, San Diego, CA, USA).

Fig. 6.

Fig. 6

Open in a new tab

Schematic of microfluidic chips for virus enrichment process. The width and the length of the microcolumns were (a) 2 mm and 10 mm, (b) 1 mm and 10 mm, (c) 1 mm and 20 mm, (d) 1 mm and 40 mm, (e) 0.5 mm and 40 mm.

2.6. Statistical analysis

Data represent mean values ± standard errors. One-way analysis of variance (ANOVA) was used to compare the mean values among groups. P values < 0.05 were considered to indicate statistical significance. The number of test samples (N) for each experiment was four.

3. Results

3.1. Virus purification

Fig. 7 shows the results of the virus purification process from virus suspensions which included 5%, 10%, 15%, 20% FBS protein. Before chromatography, the hemagglutination reaction gave negative results even though the suspensions contained virus because FBS protein inhibits hemagglutination [23]. After chromatography, the hemagglutination reaction gave positive results because the FBS had been removed by chromatography. These results show that hydroxyapatite chromatography on the microfluidic chip allowed the sensitive detection of viruses.

Fig. 7.

Fig. 7

Open in a new tab

Results of the virus purification process from virus suspensions which included 5%, 10%, 15%, 20% FBS protein. Before chromatography, the hemagglutination reaction gave negative results even though the suspensions contained virus because FBS protein inhibits hemagglutination. After chromatography, the hemagglutination reaction gave positive results because the FBS proteins in the samples were removed by chromatography.

3.2. Virus enrichment

To evaluate virus enrichment efficiency of the microfluidic chip, the amount of RNA was investigated by real-time RT-PCR. Using RNA templates of NDV from 104 to 103  pfu/mL, a standard curve was obtained and the linear regression between the Ct value and the logarithm of the virus concentration was determined. Based on the equation provided by the standard curve, the efficiencies of virus enrichment were quantified once the Ct value of the enriched NDV sample obtained from our microfluidic chip was measured by real-time RT-PCR.

Fig. 8 shows the results of virus enrichment. Five microfluidic chips with different shapes of microcolumn were prepared, as described above. The most effective enrichment was achieved using the 1-mm-wide, 20-mm-long microcolumn. Its enrichment efficiency was 7.26.

Fig. 8.

Fig. 8

Open in a new tab

Results of virus enrichment. (a) Microcolumns B, C and D are 1 mm wide. (b) Microcolumns A, C and E are equal in volume. The most effective enrichment was achieved with the microcolumn C, which is 1 mm wide and 20 mm long, providing an enrichment efficiency of 7.26. N = 4, *P < 0.05.

4. Discussion

In the virus purification process, the results of the hemagglutination reaction showed that the viruses were successfully isolated from the mixture of virus and FBS protein. A clinical sample such as an oral swab contains many impurities such as protein which can inhibit virus detection. To improve the sensitivity of virus detection, these impurities must be removed and the viruses purified. In this study, FBS protein in the sample was removed and NDV was successfully purified by on-chip hydroxyapatite chromatography.

In the virus enrichment process, the most effective enrichment was achieved with a microcolumn 1 mm wide and 20 mm long, providing an enrichment efficiency of 7.26. Microcolumns B, C and D in Fig. 8(a) are 1 mm wide. Comparison of microcolumns B and C shows more effective enrichment with microcolumn C due to its longer length, allowing more hydroxyapatite to be packed in it. Comparison of microcolumns C and D shows more effective enrichment with microcolumn C, even though microcolumn C is half the length of D. However, the path in microcolumn D is tortuous while in microcolumn C it is straight. The height equivalence to theoretical plate (HETP) in chromatography increases if the column is tortuous. According to Giddings [24], [25], HETP is inversely proportional to the square of curvature of the column [24], [25], [26]. Therefore the curvature of the column should be infinity for small HETP, so a column should have a straight structure. Microcolumns A, C and E in Fig. 8(b) are equal in volume. Comparison of microcolumn A and C shows more effective enrichment with microcolumn C because it is thinner than microcolumn A. According to Taylor's experiment, the chromatogram has a peak due to diffusion in the column [27], [28]. For more effective elution, the chromatographic peak should be sharp. The width (W) of the chromatographic peak is proportional to the column radius, and the height (H) of the chromatographic peak is inversely proportional to the cube of the column radius. To obtain a sharp peak, W should be small and H should be large. Therefore the column radius should be smaller for more effective chromatography. In our virus enrichment experiments, microcolumn C is thinner than microcolumn A, and thus provides more effective enrichment. More effective enrichment was achieved with microcolumn C than with microcolumn E, even though E is thinner than C, because E has a tortuous shape while microcolumn C is straight.

We here demonstrated purification and enrichment of viruses on a microfluidic chip. Such a simple sample processing unit can be integrated with other units such as extraction of viral RNA and detection of viral subtype on a single microfluidic chip. Viral RNA is specifically adsorbed to silica when the solution contains chaotropic agent such as guanidine salt. The adsorbed RNA can be eluted by low-salt buffer such as nuclease-free water. A silica-packed microcolumn for viral RNA extraction is producible like hydroxyapatite microcolumn of this study. Furthermore, a viral detection could be achieved by immobilizing peptide nucleic acids (PNA) for the viral genome capture to a sample recovery chamber in this microfludic chip. PNA is an RNA/DNA mimic in which the phosphate deoxyribose backbone is replaced by a neutral amide backbone composed of N-(2-aminoethyl) glycine linkage [29], [30]. Base pairing by PNAs is not affected by intrastrand electrostatic repulsion and occurs with high affinity and enhanced rates of association with strict sequence specificity such as virus subtype. Integration of such units on a single microfluidic chip will allow the continuous treatment of the clinical samples in an enclosed region with low risk of contamination and infection to the operators. Therefore, we believe the microfluidic chip presented here has a significant potential for easy and rapid diagnosis of the infectious diseases.

5. Conclusions

In this paper we proposed a microfluidic chip with a microcolumn for hydroxyapatite chromatography. Clinical samples from patients contain many impurities which can inhibit the detection of viruses. Purification of viruses in the clinical sample allows the sensitive detection of virus. And in order to detect a virus infection at an early stage, it is very important to enrich the low-concentration virus suspension. Using our microfluidic chip, we succeeded in purifying and enriching NDV, showing that the microfluidic chip allows pretreatment of samples for accurate diagnosis of viral infectious diseases. Furthermore, we proposed a novel and simple switching valve which can switch the microchannels by hand. The switching valve has the important advantage of being very easy to fabricate and it does not need any driving source. Therefore our microfluidic chip can be produced at low cost and used by anybody, anywhere and anytime.

Acknowledgements

This work was supported in part by the Nano-Macro Materials, Devices and System Research Alliance Project from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT).

Biographies

Miyako Niimi is a master student at the Graduate School of Engineering, Nagoya University, Japan. Her research interests are mechanical engineering and micro-total analysis systems.

Taisuke Masuda is an assistant professor at the Graduate School of Engineering, Nagoya University, Japan. He obtained his PhD in engineering from the Graduate School of Engineering, Oita University, Japan in 2006. His research interests focus on the biomedical engineering and bio-MEMS.

Kunihiro Kaihatsu is a Specially Appointed Associate Professor at the Department of Organic Fine Chemicals in the Institute of Scientific and Industrial Research, Osaka University. He obtained his PhD in chemistry from the Graduate School of Science, Kobe University, Japan in 2001. His current interests are in the development of antiviral agents and diagnostic device with emphasis on influenza viruses.

Nobuo Kato is Professor at The Institute of Scientific and Industrial Research, Osaka University, Japan. His research interests are in the area of chemical biology, natural products chemistry and medicinal chemistry.

Shota Nakamura is an assistant professor at the Research Institute for Microbial Diseases, Osaka University, Japan. He obtained his PhD in pharmaceutical sciences from the Graduate School of Pharmaceutical Sciences, Osaka University, Japan in 2006. His research interests focus on the genomics and metagenomics in microbiology.

Takaaki Nakaya is Professor at the Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan. His current research projects are to understand molecular mechanism of virus pathogenesis, especially influenza viruses, and metagenomic analysis of viral infections in humans.

Fumihito Arai is Professor at the Graduate School of Engineering, Nagoya University, Japan. He is mainly engaging in the research fields of micro- and nano-robotics and its application to the micro- and nano-assembly and cell manipulation, bio-automation systems, medical robotic systems, micro- and nano-electro mechanical systems, intelligent robotic systems.

Footnotes

Appendix A

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.snb.2014.04.011.

Appendix A. Supplementary data

mmc1.jpg (659.4KB, jpg)

References

  • 1.Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y., Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R., Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S., Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.E., Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S., Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M., Skowronski D.M., Upton C., Roper R.L. The genome sequence of the SARS-associated coronavirus. Science. 2003;300:1399–1404. doi: 10.1126/science.1085953. [DOI] [PubMed] [Google Scholar]
  • 2.Peiris J.S.M., Guan Y., Yuen K.Y. Severe acute respiratory syndrome. Nat. Med. 2004;10:S88–S97. doi: 10.1038/nm1143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cao Q., Mahalanabis M., Chang J., Carey B., Hsieh C., Stanley A., Odell C.A., Mitchell P., Feldman J., Pollock N.R., Klapperich C.M. Microfluidic chip for molecular amplification of influenza A RNA in human respiratory specimens. Plos One. 2012;7 doi: 10.1371/journal.pone.0033176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Xu R., Ekiert D.C., Krause J.C., Hai R., Crowe J.E., Wilson I.A. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010;328:357–360. doi: 10.1126/science.1186430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Mardis E.R. Next-generation DNA sequencing methods. Annu. Rev. Genom. Hum. G. 2008;9:387–402. doi: 10.1146/annurev.genom.9.081307.164359. [DOI] [PubMed] [Google Scholar]
  • 6.Nakamura S., Yang C.S., Sakon N., Ueda M., Tougan T., Yamashita A., Goto N., Takahashi K., Yasunaga T., Ikuta K., Mizutani T., Okamoto Y., Tagami M., Morita R., Maeda N., Kawai J., Hayashizaki Y., Nagai Y., Horii T., Iida T., Nakaya T. Direct metagenomic detection of viral pathogens in nasal and fecal specimens using an unbiased high-throughput sequencing approach. Plos One. 2009;4 doi: 10.1371/journal.pone.0004219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.de Mello A.J., Beard N. Dealing with ‘real’ samples: sample pre-treatment in microfluidic systems. Lab. Chip. 2003;3:11n–19n. doi: 10.1039/b301019h. [DOI] [PubMed] [Google Scholar]
  • 8.Tiselius A., Hjerten S., Levin O. Protein chromatography on calcium phosphate columns. Arch. Biochem. Biophys. 1956;65:132–155. doi: 10.1016/0003-9861(56)90183-7. [DOI] [PubMed] [Google Scholar]
  • 9.Bernardi G., Kawasaki T. Chromatography of polypeptides and proteins on hydroxyapatite columns. Biochim. Biophys. Acta. 1968;160:301. doi: 10.1016/0005-2795(68)90203-1. [DOI] [PubMed] [Google Scholar]
  • 10.Cummings L.J., Snyder M.A., Brisack K. Protein chromatography on hydroxyapatite columns. Method. Enzymol. 2009;463:387–404. doi: 10.1016/S0076-6879(09)63024-X. [DOI] [PubMed] [Google Scholar]
  • 11.Hjerten S. Calcium phosphate chromatography of normal human serum and of electrophoretically isolated serum proteins. Biochim. Biophys. Acta. 1959;31:216–235. doi: 10.1016/0006-3002(59)90459-7. [DOI] [PubMed] [Google Scholar]
  • 12.Thomas C., Jr., Abelson J. Proc. Nucl. Acid Res. Harper and Row; New York: 1966. The isolation and characterization of DNA from bacteriophage; pp. 553–561. [Google Scholar]
  • 13.Stanley W.M. The precipitation of purified concentrated influenza virus and vaccine on calcium phosphate. Science. 1945;101:332–335. doi: 10.1126/science.101.2622.332. [DOI] [PubMed] [Google Scholar]
  • 14.Kurosawa Y., Saito M., Kobayashi S., Okuyama T. Purification of dengue virus particles by one-step ceramic hydroxyapatite chromatography. World J. Vaccines. 2012;2:155–160. [Google Scholar]
  • 15.Berry E.D., Siragusa G.R. Hydroxyapatite adherence as a means to concentrate bacteria. Appl. Environ. Microb. 1997;63:4069–4074. doi: 10.1128/aem.63.10.4069-4074.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Bernardi G., Giro M.G., Gaillard C. Chromatography of polypeptides and proteins on hydroxyapatite columns –some new developments. Biochim. Biophys. Acta. 1972;278:409. doi: 10.1016/0005-2795(72)90001-3. [DOI] [PubMed] [Google Scholar]
  • 17.Wassell D.T.H., Hall R.C., Embery G. Adsorption of bovine serum-albumin onto hydroxyapatite. Biomaterials. 1995;16:697–702. doi: 10.1016/0142-9612(95)99697-k. [DOI] [PubMed] [Google Scholar]
  • 18.Anderson J.R., Chiu D.T., Jackman R.J., Cherniavskaya O., McDonald J.C., Wu H.K., Whitesides S.H., Whitesides G.M. Fabrication of topologically complex three-dimensional microfluidic systems in PDMS by rapid prototyping. Anal. Chem. 2000;72:3158–3164. doi: 10.1021/ac9912294. [DOI] [PubMed] [Google Scholar]
  • 19.de Leeuw O., Peeters B. Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae. J. Gen. Virol. 1999;80:131–136. doi: 10.1099/0022-1317-80-1-131. [DOI] [PubMed] [Google Scholar]
  • 20.Nagai Y., Klenk H.D., Rott R. Proteolytic cleavage of viral glycoproteins and its significance for virulence of newcastle-disease virus. Virology. 1976;72:494–508. doi: 10.1016/0042-6822(76)90178-1. [DOI] [PubMed] [Google Scholar]
  • 21.Park J.E., Cruz D.J.M., Shin H.J. Trypsin-induced hemagglutination activity of porcine epidemic diarrhea virus. Arch. Virol. 2010;155:595–599. doi: 10.1007/s00705-010-0620-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Nakaya T., Cros J., Park M.S., Nakaya Y., Zheng H.Y., Sagrera A., Villar E., Garcia-Sastre A., Palese P. Recombinant Newcastle disease virus as a vaccine vector. J. Virol. 2001;75:11868–11873. doi: 10.1128/JVI.75.23.11868-11873.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Stavitsky A.B. Micromethods for the study of proteins and antibodies .1. Procedure and general applications of hemagglutination and hemagglutination-inhibition reactions with tannic acid and protein-treated red blood cells. J. Immunol. 1954;72:360–367. [PubMed] [Google Scholar]
  • 24.Giddings J.C. Coiled columns and resolution in gas chromatography. J. Chromatogr. 1960;3:520–523. [Google Scholar]
  • 25.Giddings J.C. Plate height in coiled columns. J. Chromatogr. 1964;16 doi: 10.1016/s0021-9673(01)82513-9. 444-&. [DOI] [PubMed] [Google Scholar]
  • 26.Tsuda T., Novotny M. Packed microcapillary columns in high-performance liquid-chromatography. Anal. Chem. 1978;50:271–275. [Google Scholar]
  • 27.Rocca J.L., Higgins J.W., Brownlee R.G. Peak variance as a function of Hplc column length and diameter. J. Chromatogr. Sci. 1985;23:106–113. [Google Scholar]
  • 28.Taylor G.I. Diffusion and mass transport in tubes. P. Phys. Soc. Lond. B. 1954;67:857–869. [Google Scholar]
  • 29.Kaihatsu K., Kato N. Genome specific diagnosis of influenza virus strains by hairpin-type peptide nucleic acid. Antivir. Res. 2011;90 A70-A70. [Google Scholar]
  • 30.Kaihatsu K., Sawada S., Nakamura S., Nakaya T., Yasunaga T., Kato N. Sequence-specific and visual identification of the influenza virus ns gene by azobenzene-tethered bis-peptide nucleic acid. Plos One. 2013;8 doi: 10.1371/journal.pone.0064017. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

mmc1.jpg (659.4KB, jpg)

Articles from Sensors and Actuators. B, Chemical are provided here courtesy of Elsevier

RESOURCES